Johnson & Johnson (Innovative Medicine)
Profile managed by Bizz IdDescription
Products
15 productsBrand: RYBREVANT FASPRO (amivantamab-vmjw). Oncology.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: RYBREVANT (amivantamab-vmjw). Oncology. In registration: frontline NSCLC with chemotherapy (PAPILLON) and head and neck cancer (ORIGAMI-4); Phase 3: colorectal cancer (ORIGAMI-2, ORIGAMI-3) and head and neck (ORIGAMI-5).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: DARZALEX. Oncology. Partner: Genmab. New indication in registration: frontline transplant-ineligible multiple myeloma (CEPHEUS).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: DARZALEX FASPRO (daratumumab and hyaluronidase-fihj). Oncology. Partners: Genmab (daratumumab), Halozyme (ENHANZE platform).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Daratumumab: see suppliers → · Hyaluronidase: see suppliers →
Brand: PROCRIT. Oncology (per product list).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: SIMPONI ARIA. Immunology.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: SIMPONI. Immunology.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: TREMFYA. Immunology. Partner: MorphoSys. In registration: juvenile psoriatic arthritis; Phase 3: paediatric Crohn's disease (MACARONI-23) and paediatric ulcerative colitis (QUASAR JR).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: REMICADE. Immunology.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: IMAAVY (nipocalimab-aahu). Immunology. In registration: warm autoimmune hemolytic anemia (ENERGY); Phase 3: SLE, Sjogren's disease, HDFN, FNAIT; Phase 2: idiopathic inflammatory myopathy.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Metastatic castration-resistant prostate cancer, Phase 3 (KLK2-comPAS, KLK2-PASenger).
Under development
Finished product (FDF)
Verified on 2026-10-21
R/R multiple myeloma (TRIlogy-4, TRIlogy-5) and transplant-ineligible NDMM with daratumumab (TRIlogy-7), Phase 3.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: TALVEY (talquetamab-tgvs). Oncology. In registration: R/R multiple myeloma (MonumenTAL-3, MonumenTAL-6) and in combination with TECVAYLI (RedirecTT-1, MonumenTAL-6); Phase 3: transplant-ineligible NDMM (MajesTEC-7).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: TECVAYLI (teclistamab-cqyv). Oncology. In registration: MM 1-3 prior lines (MajesTEC-3), R/R MM CD38-exposed (MajesTEC-9) and in combination with TALVEY; Phase 3: NDMM (MajesTEC-4, MajesTEC-7).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: STELARA. Immunology. New indications in registration: paediatric ulcerative colitis (UNIFI JR) and juvenile psoriatic arthritis (PSUMMIT JR).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21